Document:

Exhibit 10.15

 

AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT

 

THIS AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of September, 2019, by and
among Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and each of the investors listed
on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.

 

RECITALS

 

WHEREAS, the Company
and the holders of capital stock of the Company previously entered into that certain Amended and Restated Investors’ Rights
Agreement dated as of September 26, 2018 (“Prior Agreement”);

 

WHEREAS, the Company
and the Investors purchasing Series D Preferred Stock (the “Series D Investors”) are parties to the
Series D Preferred Stock Purchase Agreement of even date herewith (the “Purchase Agreement”); and

 

WHEREAS, in order
to induce the Company to enter into the Purchase Agreement and to induce the Series D Investors to invest funds in the Company
pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the
Investors to cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from
the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth
in this Agreement.

 

AGREEMENT

 

NOW, THEREFORE,
the parties hereby agree as follows:

 

1.            Definitions.
For purposes of this Agreement:

 

1.1          “Affiliate”
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by or is under
common control with such Person, including without limitation any general partner, managing member, officer or director of such
Person or any venture capital or other investment fund now or hereafter existing that is controlled by one or more general partners
or managing members of, or shares the same management company or investment advisor with, such Person.

 

1.2          “Board
of Directors” means the Board of Directors of the Company.

 

1.3          “Common
Stock” means shares of the Company’s common stock, par value $0.00001 per share.

 

1.4          “Damages”
means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act,
the Exchange Act or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof)
arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration
statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary
to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any
of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated
under the Securities Act, the Exchange Act or any state securities law.

 

     

     

    

 

1.5          “Derivative
Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly
or indirectly), Common Stock, including options and warrants.

 

1.6          “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

1.7          “Excluded
Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary
pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction;
(iii) a registration on any form that does not include substantially the same information as would be required to be included
in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.

 

1.8          “Form S-1”
means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities
Act subsequently adopted by the SEC.

 

1.9          “Form S-3”
means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently
adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with
the SEC.

 

1.10        “GAAP”
means generally accepted accounting principles in the United States.

 

1.11        “Holder”
means any holder of Registrable Securities who is a party to this Agreement.

 

1.12        “Immediate
Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law, including adoptive relationships, of a natural person
referred to herein.

 

1.13        “Initiating
Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 

1.14        “IPO”
means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 

1.15        “Key
Employee” means any officer or other executive-level employee (including, division director and vice president-level
positions) of the Company as well as any employee who, either alone or in concert with others, develops, invents, programs or designs
any Company Intellectual Property (as defined in the Purchase Agreement).

 

1.16        “New
Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights,
options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible
or exchangeable into or exercisable for such equity securities.

 

1.17        “Person”
means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

1.18        “Registrable
Securities” means (i) the Common Stock issuable or issued upon conversion of the Series D Preferred Stock,
Series C Preferred Stock or the Series B Preferred Stock; (ii) any Common Stock issued or issuable (directly or
indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Series D Investors, Series C
Investors or the Series B Investors after the date hereof; (iii) any Common Stock issued as (or issuable upon the conversion
or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in
exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however,
any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned
pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights
have terminated pursuant to Section 2.13 of this Agreement.

 

    2

     

    

 

1.19        “Registrable
Securities then outstanding” means the number of shares of Common Stock determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly)
pursuant to then exercisable and/or convertible securities that are Registrable Securities.

 

1.20        “Restated
Certificate” means the Amended and Restated Certificate of Incorporation of the Company.

 

1.21        “Restricted
Securities” means the securities of the Company required to be notated with the legend set forth in Section 2.12(b) hereof.

 

1.22        “SEC”
means the Securities and Exchange Commission.

 

1.23        “SEC
Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

 

1.24        “SEC
Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

 

1.25        “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

1.26        “Selling
Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable
Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel
borne and paid by the Company as provided in Section 2.6.

 

1.27        “Series A
Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.00001 per share.

 

1.28        “Series B
Investor” means an Investor holding Series B Preferred Stock.

 

1.29        “Series B
Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.00001 per share.

 

1.30        “Series C
Investor” means an Investor holding Series C Preferred Stock.

 

1.31        “Series C
Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.00001 per share.

 

1.32         “Series D
Preferred Stock” means shares of the Company’s Series D Preferred Stock, par value $0.00001 per share.

 

    3

     

    

 

2.            Registration
Rights. The Company covenants and agrees as follows:

 

2.1          Demand
Registration.

 

(a)             Form S-1
Demand. If at any time after the earlier of (i) three (3) years after the date of this Agreement or (ii) one
hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from
the Holders of at least sixty-five percent (65%) of the Registrable Securities then outstanding that the Company file a Form S-1
registration statement for which the anticipated aggregate offering price would exceed $10,000,000, then the Company shall (x) within
ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders
other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the
date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering
all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested
to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within
twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and
2.3.

 

(b)             Form S-3
Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from
the Holders of at least sixty-five percent (65%) of the Registrable Securities then outstanding that the Company file a Form S-3
registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering
price of at least $1,000,000, then the Company shall (i) within ten (10) days after the date such request is given, give
a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within
forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement
under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders,
as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given,
and in each case, subject to the limitations of Sections 2.1(c) and 2.3.

 

(c)             Notwithstanding
the foregoing obligations, if the Company furnishes to the Holders requesting a registration pursuant to this Section 2.1
a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors
it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective
or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action
would (i) materially interfere with a significant acquisition, corporate reorganization or other similar transaction involving
the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for
preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange
Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect
to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request
of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once
in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account
or that of any other stockholder during such ninety (90) day period other than in an Excluded Registration.

 

    4

     

    

 

(d)            The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a) (i) during
the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date
that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the
Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective;
(ii) after the Company has effected two (2) registrations pursuant to Section 2.1(a); or (iii) if the
Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any
action to effect, any registration pursuant to Section 2.1(b) during the period that is thirty (30) days before
the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective
date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable
efforts to cause such registration statement to become effective. A registration shall not be counted as “effected”
for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared
effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration
expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which
case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d).

 

2.2          Company
Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for
stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such
securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder
notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company,
the Company shall, subject to the provisions of Section 2.3, cause to be registered all of the Registrable Securities
that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw
any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or
not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of
such withdrawn registration shall be borne by the Company in accordance with Section 2.6.

 

2.3          Underwriting
Requirements.

 

(a)             If,
pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request
by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1,
and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Board of Directors
and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder
to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation
in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided
herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided
in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for
such underwriting. Notwithstanding any other provision of this Section 2.3, if the managing underwriter(s) advise(s) the
Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the
Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto,
and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable
Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities
owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however,
that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all
other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the
above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred
(100) shares.

 

    5

     

    

 

(b)            In
connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2,
the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders
accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as
the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total
number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number
of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible
with the success of the offering, then the Company shall be required to include in the offering only that number of such securities,
including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize
the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered
can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the
selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or
in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in
accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to
the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities
included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely
excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty
percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling
Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities
are included in such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment,
for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners,
retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners,
retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed
to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall
be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,”
as defined in this sentence.

 

2.4            Obligations
of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities,
the Company shall, as expeditiously as reasonably possible:

 

(a)            prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of at least sixty-five percent
(65%) of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one
hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed;
provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time
equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company,
from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities
on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules,
such one hundred twenty (120) day period shall be extended, if necessary, to keep the registration statement effective until all
such Registrable Securities are sold;

 

(b)            prepare
and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities
covered by such registration statement;

 

    6

     

    

 

(c)            furnish
to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable
Securities;

 

(d)            use
its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that
the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states
or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities
Act;

 

(e)            in
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the underwriter(s) of such offering;

 

(f)             use
its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed
on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities
issued by the Company are then listed;

 

(g)            provide
a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration;

 

(h)            promptly
make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant
to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by
the selling Holders, all financial and other records, pertinent corporate documents and properties of the Company, and cause the
Company’s officers, directors, employees and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant or agent, in each case, as necessary or advisable to verify the accuracy of the
information in such registration statement and to conduct appropriate due diligence in connection therewith;

 

(i)             notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 

(j)             after
such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement
such registration statement or prospectus.

 

In addition, the Company
shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under
the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may
implement a trading program under Rule 10b5-1 of the Exchange Act.

 

2.5          Furnish
Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2
with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information
regarding itself, the Registrable Securities held by it and the intended method of disposition of such securities as is reasonably
required to effect the registration of such Holder’s Registrable Securities.

 

    7

     

    

 

2.6          Expenses
of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications
pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees;
fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders
selected by the Holders of at least sixty-five percent (65%) of the Registrable Securities to be registered (“Selling
Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not
be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration
request is subsequently withdrawn at the request of the Holders of at least sixty-five percent (65%) of the Registrable Securities
to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities
that were to be included in the withdrawn registration), unless the Holders of at least sixty-five percent (65%) of the Registrable
Securities agree to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case
may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change
in the condition, business or prospects of the Company from that known to the Holders at the time of their request and have withdrawn
the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of
such expenses and shall not forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b). All
Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by
the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.

 

2.7          Delay
of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation
of this Section 2.

 

2.8          Indemnification.
If any Registrable Securities are included in a registration statement under this Section 2:

 

(a)             To
the extent permitted by law, the Company will indemnify and hold harmless each selling Holder and the partners, members, officers,
directors and stockholders of each such Holder; legal counsel, accountants and investment advisors for each such Holder; any underwriter
(as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within
the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter,
controlling Person or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating
or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however,
that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of
any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably
withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions
made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration.

 

(b)            To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and
each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company
within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities
Act), any other Holder selling securities in such registration statement and any controlling Person of any such underwriter or
other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or
omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly
for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned
Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding
from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained
in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement
is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that
in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and
2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder),
except in the case of fraud or willful misconduct by such Holder.

 

    8

     

    

 

(c)            Promptly
after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action (including
any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim
in respect thereof is to be made against any indemnifying party under this Section 2.8, give the indemnifying party
notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent
the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to
assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified
party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right
to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified
party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between
such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying
party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to
the indemnified party under this Section 2.8, to the extent that such failure materially prejudices the indemnifying
party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability
that it may have to any indemnified party otherwise than under this Section 2.8.

 

(d)            To
provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8
but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration
of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding
the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities
Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8,
then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities or expenses to
which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault
of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that
resulted in such loss, claim, damage, liability or expense, as well as to reflect any other relevant equitable considerations.
The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things,
whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates
to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge,
access to information, and opportunity to correct or prevent such statement or omission; provided, however, that,
in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such
Registrable Securities offered and sold by such Holder pursuant to such registration statement and (y) no Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution
from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a
Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder
pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses
paid by such Holder), except in the case of willful misconduct or fraud by such Holder.

 

    9

     

    

 

(e)            Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered
into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.

 

(f)             Unless
otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities
in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.

 

2.9          Reports
Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or
regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration
or pursuant to a registration on Form S-3, the Company shall:

 

(a)            make
and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all
times after the effective date of the registration statement filed by the Company for the IPO;

 

(b)            use
commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company
under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements);
and

 

(c)            furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety
(90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act and the
Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant
whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the
most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such
other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits
the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements
under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).

 

2.10        Limitations
on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written
consent of the Holders of at least sixty-five percent (65%) of the Registrable Securities then outstanding, enter into any agreement
with any holder or prospective holder of any securities of the Company that (i) would provide to such holder the right to
include securities in any registration on other than a subordinate basis after all Holders have had the opportunity to include
in the registration and offering all shares of Registrable Securities that they wish to so include or (ii) allow such holder
or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided
that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Section 6.9.

 

    10

     

    

 

2.11        “Market
Stand-off” Agreement. Each holder of Series D Preferred Stock, Series C Preferred Stock, Series B Preferred
Stock, Series A Preferred Stock and Common Stock hereby agrees that it will not, without the prior written consent of the
managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO, and ending on the date
specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the
IPO, or such other period as may be requested by the Company or an underwriter (but in no event more than two hundred sixteen (216)
days) to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst
recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE
Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell;
sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase;
or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable
or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement
for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above
is to be settled by delivery of Common Stock or other securities, in cash or otherwise. The foregoing provisions of this Section 2.11
shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement
for such IPO and shall be applicable to the Holders only if all officers and directors of the Company and holders of at least one
percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding
Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock and Series A Preferred Stock)
are subject to similar restrictions. The underwriters in connection with such registration are intended third-party beneficiaries
of this Section 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they
were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in
connection with such registration that are consistent with this Section 2.11 or that are necessary to give further
effect thereto.

 

2.12        Restrictions
on Transfer.

 

(a)            The
Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock and
the Common Stock shall not be sold, pledged, or otherwise transferred in violation of this Agreement, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge or transfer, except
upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the
Securities Act. A transferring holder of Series D Preferred Stock, Series C Preferred Stock, Series B Preferred
Stock, Series A Preferred Stock or Common Stock will cause any proposed purchaser, pledgee or transferee of such stock held
by such holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.

 

(b)            Each
certificate, instrument or book entry representing Restricted Securities shall (unless otherwise permitted by the provisions of
Section 2.12(c)) be notated with a legend substantially in the following form:

 

THE SHARES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN
CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER
THE SECURITIES ACT OF 1933.

 

    11

     

    

 

THE SHARES REPRESENTED BY THIS
CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
BY AND AMONG THE HOLDER OF THE SECURITIES, THE COMPANY AND CERTAIN STOCKHOLDERS OF THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE
OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.

 

THE SHARES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER INCLUDING RESTRICTIONS FOR A PERIOD NOT TO EXCEED 180 DAYS FOLLOWING THE EFFECTIVE
DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY’S SECURITIES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY
THE HOLDER WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER.

 

The holders of Restricted
Securities consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted
Securities in order to implement the restrictions on transfer set forth in this Section 2.12.

 

(c)            The
holder of each certificate representing Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects
with the provisions of this Section 2. Before any proposed sale, pledge or transfer of any Restricted Securities, unless
there is in effect a registration statement under the Securities Act covering the proposed transaction or, following the IPO, the
transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention
to effect such sale, pledge or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge
or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense
by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the
Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities
Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge or transfer of such Restricted
Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto;
or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge,
or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of
such Restricted Securities shall be entitled to sell, pledge or transfer such Restricted Securities in accordance with the terms
of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action”
letter (x) in any transaction in compliance with SEC Rule 144 or (y) in any transaction in which such Holder distributes
Restricted Securities to an Affiliate of such Holder for no consideration; provided that, with respect to transfers following
the IPO under the foregoing clause (y), each transferee agrees in writing to be subject to the terms of this Section 2.12.
Each certificate, instrument or book entry evidencing the Restricted Securities transferred as above provided shall be notated
with, except if such transfer is made pursuant to SEC Rule 144 or pursuant to an effective registration statement under the
Securities Act, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate, instrument
or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company,
such legend is not required in order to establish compliance with any provisions of the Securities Act.

 

2.13        Termination
of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration
pursuant to Sections 2.1 or 2.2 shall terminate upon the earliest to occur of:

 

    12

     

    

 

(a)            the
closing of a Deemed Liquidation Event, as such term is defined in the Company’s Restated Certificate;

 

(b)            such
time after the IPO as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all
of such Holder’s shares without limitation during a three-month period without registration; and

 

(c)            the
fifth (5th) anniversary of the IPO.

 

3.            Information
Rights.

 

3.1          Delivery
of Financial Statements. The Company shall deliver to each Holder, provided that the Board of Directors has not reasonably
determined that such Holder is (or, in the case of a Holder that is an individual, is employed by or serves as a consultant to)
a competitor of the Company (provided that an Investor shall not be deemed to be a competitor of the Company solely for owning
an equity interest in one or more companies that may be considered competitive with the Company):

 

(a)            as
soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company, (i) a
balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement
of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public
accountants of nationally recognized standing selected by the Company and approved by the Board of Directors; provided that the
requirement for audited financial statements and/or independent public accountants of nationally recognized standing may be waived
by the written consent of the Holders, owing at least sixty-five percent (65%) of the outstanding and issued Series B Preferred
Stock, Series C Preferred Stock and Series D Preferred Stock, voting together as a single class on an as-converted to
Common Stock basis;

 

(b)            as
soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter and an unaudited balance
sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be
subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with
GAAP);

 

(c)            as
soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement and statement
of cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP
(except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all
notes thereto that may be required in accordance with GAAP), including a comparison of performance against (i) the Budget
(as defined below) and (ii) the prior year’s actual results;

 

(d)            as
soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next
fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis,
including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other
budgets or revised budgets prepared by the Company;

 

(e)            with
respect to the financial statements called for in Section 3.1(a), Section 3.1(b) and Section 3.1(c),
an instrument executed by the chief financial officer and chief executive officer of the Company certifying that such financial
statements were prepared in accordance with GAAP consistently applied with prior practice for earlier periods (except as otherwise
set forth in Section 3.1(b) and Section 3.1(c)) and fairly present the financial condition of the
Company and its results of operation for the periods specified therein; and

 

    13

     

    

 

(f)             such
other information relating to the financial condition, operating information, business, prospects or corporate affairs of the Company
as any Holder may from time to time reasonably request; provided, however, that the Company shall not be obligated
under this Section 3.1 to provide information (i) that the Company reasonably determines in good faith to be a
trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the
Company) or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its
counsel.

 

If, for any period, the
Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial
statements delivered pursuant to the foregoing sections shall be the consolidated financial statements of the Company and all such
consolidated subsidiaries.

 

Notwithstanding anything
else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this Section 3.1
during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of
a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration
statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be
reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration
statement to become effective.

 

3.2          Inspection.
The Company shall permit each Holder (provided that the Board of Directors has not reasonably determined that such Holder
is a competitor of the Company), at such Holder’s expense, to visit and inspect the Company’s properties; examine its
books of account and records; and discuss the Company’s affairs, finances and accounts with its officers, during normal business
hours of the Company as may be reasonably requested by the Holder; provided, however, that the Company shall not
be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith
considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form
acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company
and its counsel.

 

3.3          Termination
of Information Rights. The covenants set forth in Section 3.1 and Section 3.2 shall terminate and be
of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes
subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon
a Deemed Liquidation Event, as such term is defined in the Company’s Restated Certificate, unless the consideration received
by the Investors is in the form of securities that are privately held, whichever event occurs first.

 

3.4          Confidentiality.
Each Investor agrees that such Investor will keep confidential and will not disclose, divulge or use for any purpose (other than
to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this
Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information
(a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4
by such Investor), (b) is or has been independently developed or conceived by any Investor without use of the Company’s
confidential information, or (c) is or has been made known or disclosed to any Investor by a third party without a breach
of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor
may disclose confidential information (i) to its attorneys, accountants, consultants and other professionals to the extent
necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser
of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.4;
(iii) to any Affiliate, partner, member, stockholder or wholly owned subsidiary of such Investor in the ordinary course of
business, provided that such Investor informs such Person that such information is confidential and directs such Person
to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that such
Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required
disclosure.

 

    14

     

    

 

4.            Rights
to Future Stock Issuances.

 

4.1          Right
of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor. An Investor
shall be entitled to apportion the right of first offer hereby granted to it among itself and its Affiliates in such proportions
as it deems appropriate. The Company shall not be required to offer or sell New Securities to any Investor who is not an accredited
investor within the meaning of Rule 501 under the Securities Act or who would otherwise cause the Company to be in violation
of applicable federal and state securities laws.

 

(a)            The
Company shall give notice (the “Offer Notice”) to each Investor, stating (i) its bona fide intention to
offer such New Securities, (ii) the number of such New Securities to be offered and (iii) the price and terms, if any,
upon which it proposes to offer such New Securities.

 

(b)            By
notification to the Company within twenty (20) days after the Offer Notice is given, each Investor may elect to purchase or otherwise
acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the
proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable,
of the Preferred Stock and any other Derivative Securities then held, by such Investor bears to the total Common Stock of the Company
then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities).
At the expiration of such twenty (20) day period, the Company shall promptly notify each Investor that elects to purchase or acquire
all the shares available to it (each, a “Fully Exercising Investor”) of any other Investor’s failure to
do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor
may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to
that portion of the New Securities for which Investors were entitled to subscribe but that were not subscribed for by the Investors
which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or
exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears
to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the
Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed
shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of ninety (90) days
of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c).

 

(c)            If
all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 4.1(b),
the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b),
offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and
upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement
for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the
execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless
first reoffered to the Investors in accordance with this Section 4.1.

 

    15

     

    

 

(d)            The
right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as defined in the
Company’s Restated Certificate) or (ii) shares of Common Stock issued in the IPO.

 

4.2          Termination.
The covenants set forth in Section 4.1 shall terminate and be of no further force or effect (i) immediately before
the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or
15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Restated
Certificate, whichever event occurs first.

 

5.            Additional
Covenants.

 

5.1          Insurance.
The Company has, from financially sound and reputable insurers, Directors and Officers liability insurance in an amount and on
terms and conditions satisfactory to the Board of Directors (including the director designated by Piper Jaffray Merchant Banking
Fund II, L.P. (“PJMB”)), and will use commercially reasonable efforts to cause such insurance policies to be
maintained until such time as the Board of Directors (including the director designated by PJMB) determines that such insurance
should be discontinued.

 

5.2          Employee
Matters. The Company will cause each person now or hereafter employed by it or by any subsidiary (or engaged by the Company
or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter
into a nondisclosure and proprietary rights assignment agreement in the form approved by the Company’s Board of Directors.

 

5.3          Employee
Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of the Company who purchase,
receive options to purchase or receive awards of shares of the Company’s capital stock after the date hereof shall be required
to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year
period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or
service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months without any form
of accelerated vesting unless specifically approved by the Board of Directors, and (ii) a market stand-off provision substantially
similar to that in Section 2.11. In addition, unless otherwise approved by the Board of Directors, the Company shall
retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase
unvested shares at cost upon termination of employment of a holder of restricted stock.

 

5.4          Board
Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall
meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all
reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending
meetings of the Board of Directors. The Company shall maintain, an audit and compensation committee, each of which shall consist
of at least three (3) directors, which shall include two (2) directors designated by Telegraph Hill Partners III L.P.
The director designated by PJMB is entitled to, but is not obligated to, serve on each committee of the Board of Directors.

 

5.5          Successor
Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and
is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper
provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect
to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations
are contained in the Company’s Bylaws, its Restated Certificate, or elsewhere, as the case may be.

 

    16

     

    

 

5.6          Expenses
of Counsel. In the event of a transaction which is a Sale of the Company (as defined in the Amended and Restated Voting Agreement
of even date herewith among the Investors and the Company), the reasonable fees and disbursements of one counsel for the Holders
(“Investor Counsel”), in their capacities as stockholders, shall be borne and paid by the Company. At the outset
of considering a transaction which, if consummated would constitute a Sale of the Company, the Company shall obtain the ability
to share with the Investor Counsel (and such counsel’s clients) and shall share the confidential information (including,
without limitation, the initial and all subsequent drafts of memoranda of understanding, letters of intent and other transaction
documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing
any of the transactions which, individually or when aggregated with others would constitute the Sale of the Company. The Company
shall be obligated to share (and cause the Company’s counsel and investment bankers to share) such materials when distributed
to the Company’s executives and/or any one or more of the other parties to such transaction(s). In the event that Investor
Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense agreement or other arrangement to enhance
the ability of the parties to protect their communications and other reviewed materials under the attorney client privilege, the
Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form
and substance reasonably acceptable to Investor Counsel. In the event that one or more of the other party or parties to such transactions
require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in order to receive
such information, then the Company shall share whatever information can be shared without entry into such agreement and shall,
at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate
agreement(s) without undue burden to the clients of Investor Counsel.

 

5.7          Right
to Conduct Activities. The Company hereby agrees and acknowledges that each of Telegraph Hill Partners III L.P. (“THP”),
PJMB (together with their respective affiliates), Agilent Technologies, Inc. (“Agilent”) and Innovatus
Life Sciences Lending Fund I, LP and Innovatus Life Sciences Offshore Fund I-A, LP (together, “Innovatus”) invests
in numerous companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as
currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, THP, PJMB, Agilent
and Innovatus shall not be liable to the Company for any claim arising out of or based upon, (i) the investment by such Investor
in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of such
Investor to assist any such competitive company, whether or not such action was taken as a member of the board of directors of
such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however,
that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of
the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company
from any liability associated with his or her fiduciary duties to the Company.

 

5.8          Efforts
for Series D Redemption. Following the Company’s receipt of the Series D Redemption Request (as defined in
the Restated Certificate), the Company shall take all action and efforts that the Board of Directors deems reasonable and appropriate
to make available free cash flow for purposes of paying the Series D Redemption Price (as defined in the Restated Certificate)
to the holders of Series D Preferred Stock in accordance with the Restated Certificate.

 

5.9          Termination
of Covenants. The covenants set forth in this Section 5, except for Sections 5.6, shall terminate and be
of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes
subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon
a Deemed Liquidation Event, as such term is defined in the Company’s Restated Certificate, whichever event occurs first.

 

    17

     

    

 

6.            Miscellaneous.

 

6.1          Successors
and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee
of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust
for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such
transfer, holds at least 100,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends,
combinations and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time
after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with
respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the
Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11.
For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee
(1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that
is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together
and with those of the transferring Holder; provided further that all transferees who would not qualify individually for
assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices or taking
any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective
successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or
liabilities under or by reason of this Agreement, except as expressly provided herein.

 

6.2          Governing
Law. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed in
accordance with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the
application of any law other than the law of the State of Delaware.

 

6.3          Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including
pdf or any electronic signature e.g., www.DocuSign.com) or other transmission method and any counterpart so delivered shall
be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

6.4          Titles
and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement.

 

6.5          Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent
by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours,
then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with
a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt.
All communications shall be sent to the respective parties at their addresses as set forth on Schedule A or Schedule
B (as applicable) hereto, or to the principal office of the Company at 1505 O’Brien Drive, Suite A-1, Menlo Park,
California 94025 Attention: Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or
address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to
the Company, it shall be sent to 1505 O’Brien Drive, Suite A-1, Menlo Park, CA 94025, Attention: Chief Executive Officer,
and a copy shall also be sent to DLA Piper LLP (US), 1100 Executive Drive, Floor 11, San Diego, CA 92121, Attention: Michael Kagnoff,
email: Michael.Kagnoff@us.dlapiper.com; fax: 858.638.5122; and if notice is given to the Investors, a copy shall be sent to the
Investors’ addresses set forth on Schedule A.

 

    18

     

    

 

6.6          Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company
and the holders of least two-thirds (2/3) of Series D Preferred Stock, Series C Preferred Stock and Series B Preferred
Stock then outstanding, voting together as a single class on an as-converted to Common Stock basis; provided that the Company
may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly
in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) shall be deemed
to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s
own behalf, without the consent of any other party. Notwithstanding the foregoing, (i) this Agreement may not be amended
or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent
of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed
that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to
all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless,
by agreement with the Company, purchase securities in such transaction) and (ii) Section 5.1, Section 5.4
and clause (ii) of this Section 6.6 may not be amended, terminated or waived without the consent of PJMB.
The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not
consent in writing to such amendment, termination, or waiver. Any amendment, termination or waiver effected in accordance with
this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto.
No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed
to be or construed as a further or continuing waiver of any such term, condition or provision.

 

6.7          Severability.
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement, and such
invalid, illegal or unenforceable provision shall be reformed and construed so that it will be valid, legal and enforceable to
the maximum extent permitted by law.

 

6.8          Aggregation
of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose
of determining the availability of any rights under this Agreement.

 

6.9          Additional
Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Company’s
capital stock after the date hereof, any purchaser of such shares of capital stock may become a party to this Agreement by executing
and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor”
for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such
additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor”
hereunder.

 

6.10        Entire
Agreement. This Agreement (including any Schedules hereto) constitutes the full and entire understanding and agreement among
the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof
existing between the parties is expressly canceled.

 

    19

     

    

 

6.11        Cost
of Enforcement. The prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary disbursements
in addition to any other relief to which such party may be entitled.

 

6.12        Delays
or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such nonbreaching
or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar
breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach
or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any
party, shall be cumulative and not alternative.

 

6.13        Further
Assurances. At any time or from time to time after the date hereof, the parties agree to cooperate with each other, and at
the request of any other party, to execute and deliver any further instruments or documents and to take all such further action
as the other party may reasonably request in order to evidence or effectuate the consummation of the transactions contemplated
hereby and to otherwise carry out the intent of the parties hereunder.

 

6.14        Acknowledgment.
The Company acknowledges that the Investors are in the business of venture capital investing and therefore reviews the business
plans and related proprietary information of many enterprises, including enterprises which may have products or services which
compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors
from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete
with those of the Company.

 

6.15        Amendment
and Restatement of the Prior Agreement. The parties hereto hereby agree that the Prior Agreement shall be amended and restated
in its entirety as set forth herein and such Prior Agreement shall have no further force or effect after the date first written
above.

 

REMAINDER OF THIS PAGE INTENTIONALLY LEFT
BLANK.

 

    20

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	COMPANY 
	 	 
	 	AKOYA BIOSCIENCES, INC.
	 	 
	 	 
	 	By:	 /s/ Brian McKelligon
	 	Name:  Brian McKelligon
	 	Title:  Chief Executive Officer

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR  
	 	 
	 	PIPER JAFFRAY MERCHANT BANKING FUND , L.P.
	 	 
	 	 
	 	By:	 /s/ Thomas P. Schnettler
	 	Name:  Thomas P. Schnettler
	 	Title:  Co-CEO of PJC Capital Management II LLC,
	 	General Partner for Piper Jaffray Merchant Banking
	 	Fund II, L.P.

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR            
	 	 
	 	TELEGRAPH HILL PARTNERS III L.P.
	 	 
	 	 
	 	By:	 /s/ Robert Shepler
	 	Name:	Robert Shepler
	 	Title:	Managing Director
	 	 
	 	 
	 	THP III AFFILIATES FUND, LLC    
	 	 
	 	 
	 	By:	 /s/ Robert Shepler
	 	Name:	 Robert Shepler
	 	Title:	Managing Director

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR           
	 	 
	 	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (PVF)
	 	
	 	 
	 	By:	/s/ Sabrina Liang
	 	 	 
	 	Name: Sabrina Liang
	 	 
	 	Title: Authorized Signatory on behalf of The Board of Trustees of the Leland Stanford Junior University (PVF)

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR    
	 	 
	 	 
	 	/s/ Matthew Winkler
	 	MATTHEW WINKLER

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR    
	 	 
	 	 
	 	/s/ J. Matthew Mackowski
	 	J. MATTHEW MACKOWSKI

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR 
	 	 
	 	 
	 	/s/ Robert Shepler
	 	ROBERT SHEPLER

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR 
	 	 
	 	 
	 	/s/ Thomas Raffin
	 	THOMAS RAFFIN

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR    
	 	 
	 	 
	 	/s/ Deval Lashkari
	 	DEVAL LASHKARI

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR    
	 	 
	 	 
	 	/s/ Jeanette Welsh
	 	JEANETTE WELSH

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR    
	 	 
	 	 
	 	/s/ Rob Hart
	 	ROB HART

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR              
	 	 
	 	INNOVATUS LIFE SCIENCES LENDING FUND I, LP
	 	By: Innovatus Life Sciences GP, LP, its general partner
	 	 
	 	 
	 	By:	 /s/ Andrew Dym
	 	Name:	Andrew Dym
	 	Title:	Authorized Signatory
	 	 
	 	 
	 	INNOVATUS LIFE SCIENCES OFFSHORE FUND I-A, LP    
	 	By: Innovatus Life Sciences GP, LP, its general partner
	 	 
	 	 
	 	By:	 /s/ Andrew Dym
	 	Name:	 Andrew Dym
	 	Title:	 Authorized Signatory

 

Signature
Page to Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR
	 	 
	 	 
	 	/s/ Alex Herzick
	 	ALEX HERZICK

 

Signature Page to Amended and Restated
Investors’ Rights Agreement

 

    	 		 

     

    

  

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR
	 	 
	 	AGILENT TECHNOLOGIES, INC.
	 	 
	 	 
	 	By: 	/s/ P. Diana Chiu
	 	Name: 	P. Diana Chiu
	 	Title: 	Asst General Counsel and Asst Secretary

 

Signature Page to Amended and Restated
Investors’ Rights Agreement

 

    	 		 

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR
	 	 
	 	JOHN S. OSTERWEIS TRUSTEE FOR THE OSTERWEIS REVOCABLE TRUST DTD 9/13/93
	 	 
	 	
	 	By:      	/s/ John S. Osterweis
	 	Name: 	John S. Osterweis
	 	Title: 	Trustee

 

Signature Page to Amended and Restated
Investors’ Rights Agreement

 

    	 	 	 

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR
	 	 
	 	FLORIDA INTERNATIONAL UNIVERSITY FOUNDATION, INC.
	 	 
	 	 
	 	By: 	/s/ Jared Thomas
	 	Name:   	Jared Thomas
	 	Title: 	Authorized Signatory
	 	 	 
	 	 	By: Cambridge Associates, LLC, its investment manager

 

Signature Page to Amended and Restated
Investors’ Rights Agreement

 

    	 		 

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR
	 	 
	 	NATIONAL GEOGRAPHIC SOCIETY
	 	 
	 	 
	 	By: 	/s/ Jared Thomas
	 	Name:     	Jared Thomas
	 	Title: 	Authorized Signatory
	 	 	 
	 	 	By: Cambridge Associates, LLC, its investment manager

 

Signature Page to Amended and Restated
Investors’ Rights Agreement

 

    	 		 

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

  

	 	INVESTOR
	 	 
	 	THE LOOMIS INSTITUTE
	 	 
	 	 
	 	By: 	/s/ Jared Thomas
	 	Name:      	Jared Thomas
	 	Title: 	Authorized Signatory
	 	 	 
	 	 	By: Cambridge Associates, LLC, its investment manager

 

Signature Page to Amended and Restated
Investors’ Rights Agreement

  

    	 		 

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR
	 	 
	 	MT.
    CUBA CENTER, INC.
	 	 
	 	 
	 	By:	/s/
    Jared Thomas
	 	Name:	Jared
    Thomas
	 	Title:	Authorized
    Signatory
	 	 	 
	 	 	By: Cambridge Associates,
    LLC, its investment manager

 

Signature Page to Amended and Restated
Investors’ Rights Agreement

 

    

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR
	 	 
	 	MERCY
    COLLEGE
	 	 
	 	 
	 	By:	/s/
    Jared Thomas
	 	Name:	Jared
    Thomas
	 	Title:	Authorized
    Signatory
	 	 	 
	 	 	By: Cambridge Associates,
    LLC, its investment manager

 

Signature Page to Amended and Restated
Investors’ Rights Agreement

 

    

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

	 	INVESTOR
	 	 
	 	THE
    HOLLINS UNIVERSITY CORPORATION
	 	 
	 	 
	 	By:	/s/
    Jared Thomas
	 	Name:	Jared
    Thomas
	 	Title:	Authorized
    Signatory
	 	 	 
	 	 	By: Cambridge Associates,
    LLC, its investment manager

 

Signature Page to Amended and Restated
Investors’ Rights Agreement

 

    

     

    

 

SCHEDULE A

 

INVESTORS

 

	Name
    and Address
	Piper Jaffray Merchant Banking Fund II, L.P.

        800 Nicollet Mall

        Suite 1000

        Minneapolis, MN 55402

	Telegraph Hill Partners III L.P.

        360 Post Street, Suite 601

        San Francisco, CA 94108

	THP III Affiliates Fund, LLC

        360 Post Street, Suite 601

        San Francisco, CA 94108

	The Board of Trustees of the Leland Stanford Junior
        University (PVF)

        School & Department Fund Administration

        635 Knight Way

        Stanford, CA 94305-7297

        Ph#: 650-721-2200

        Em: direct@smc.stanford.edu

	Matthew Winkler

        [***]

        [***]

	Gary J. Latham

        [***]

        [***]

	Sejal Sheth

        [***]

        [***]

	Terry Lo

        [***]

        [***]

	Peter J. Miller

        [***]

        [***]

	Clifford C. Hoyt

        [***]

        [***]

	Yury Goltsev

        [***]

        [***]

	Nikolay Samusik

        [***]

        [***]

	Garry Nolan

        [***]

        [***]

 

    

     

    

 

	Name
    and Address
	The Board of Trustees of the Leland Stanford Junior
        University

        450 Serra Mall

        Stanford, CA 94305-2004

	WS Investment Company, LLC (2015A)

        650 Page Mill Road

        Palo Alto, CA 94304

	J. Matthew Mackowski

        [***]

        [***]

	Robert Shepler

        [***]

        [***]

	Thomas Raffin

        [***]

        [***]

	Deval Lashkari

        [***]

        [***]

	Jeanette Welsh

        [***]

        [***]

	Rob Hart

        [***]

        [***]

	Alex Herzick

        [***]

        [***]

	Agilent Technologies, Inc.

        Attention: General Counsel

        5301 Stevens Creek Blvd.

        Santa Clara, CA 95051

        Facsimile: 408-345-8958

	John S. Osterweis Trustee for The Osterweis Revocable
        Trust Dtd

        9/13/93

        Attention: Cecilia D’Ambrosio

        E-Mail: Cecilia.DAmbrosio@OSTERWEIS.com

	Innovatus Life Sciences Lending Fund I, LP

        777 Third Avenue, 25th Floor

        Attention: Claes Ekstrom

        Email: cekstrom@innovatuscp.com

	Innovatus Life Sciences Offshore Fund I-A, LP

        777 Third Avenue, 25th Floor

        Attention: Claes Ekstrom

        Email: cekstrom@innovatuscp.com

	National Geographic Society

        1145 17th Street NW

        Washington, DC 20036

 

    

     

    

 

	Name
    and Address
	Mercy College

        555 Broadway

        Dobbs Ferry, NY 10522

	Mt. Cuba Center, Inc.

        3120 Barley Mill Road

        Hockessin, DE 19707

	The Loomis Institute

        4 Batchelder Road

        Windsor, CT 06095

	Florida
    International University Foundation, Inc.
	The
    Hollins University CorporationExhibit 10.16

 

 

 

March 2, 2021

 

Frederic Pla, Ph.D.

3244 Circa de Tierra

Encinitas, CA

92924

Frederic.pla@gmail.com

 

Dear Frederic,

 

We are very excited about the prospects of your
joining Akoya Biosciences, Inc. Should you accept this offer and upon successful completion of a pre-employment background check
and drug screen we look forward to having you join the company on a date that is mutually convenient for both you and Akoya. This letter
confirms the terms of your employment.

 

Position and Duties:

You shall serve in the position of Chief Operating
Officer with Akoya Biosciences, Inc. (the “Company”) reporting to Brian McKelligon, CEO.

 

Your position, job description, manager, salary,
duties, and responsibilities may be modified from time to time at the sole discretion of Akoya Biosciences, Inc. You agree to strictly
adhere to all of the rules and regulations of Akoya Biosciences, Inc. as may be set forth in any Employee Handbook or published
policies of Akoya Biosciences, Inc. now or in the future, including all amendments to the Handbook which may be made in the future
in Akoya Biosciences, Inc.'s sole discretion (as published or amended from time to time, the "Manual”).

 

Compensation:

 

		(a)	Salary: Akoya Biosciences, Inc. shall pay you, and you agree to accept from Akoya Biosciences, Inc.
in payment for your services to Akoya Biosciences, Inc., a salary of $325,000.00 per year (the "Yearly Salary"),
payable in 24 equal installments of $13,541.67 on regular semi-monthly dates established by Akoya Biosciences, Inc., subject
to applicable tax withholding requirements. Any proposed increase of your salary, compensation or benefits must be approved by Akoya’s
CEO, Brian McKelligon.

 

		(b)	Annual Bonus. The Company has created an incentive pay plan under which you may be eligible for
an Annual cash incentive bonus (the “Bonus”). Your target cash bonus opportunity (the “Bonus”) will be
equal to 45% of your gross earnings in the calendar year. Any bonus will be based on a combination of your personal achievement
as well as the Company’s ability to meet its financial and operational performance objectives. The payment of any Bonus shall be
subject to your continued employment through the date of payment by the Company.

 

		(c)	Incentive Stock Options. The Company will offer you participation in an Equity Incentive Program.
Subject to approval by the Board of Directors of the Company (the “Board”), you will
be provided an Option to acquire the number of shares equivalent to 850,000 shares of the Company’s common stock under the
Company’s stock option plan (the “Option”). 25% of the shares subject to the Option will vest on the first anniversary
of your date of employment, with the remaining 75% of the shares subject to the Option vesting in equal monthly installments over
the subsequent 36 months on the same day of the month as your date of employment, subject to your continued service to the Company through
each applicable vesting date. The exercise price per share of the Option will be equal to the fair market value per share of the Company’s
common stock on the date the Option is granted, as determined by the Board in good faith. There is no guarantee that the Internal Revenue
Service will agree with this value. You should consult with your own tax advisor concerning the tax consequences associated with accepting
the Option.

 

1080
O’Brien Drive. Suite A, Menlo Park, CA 94025 | 855.896.8401 | www.akoyabio.com | 100 Campus Drive, 6th Floor, Marlborough,
MA 01752

 

    

     

    

 

 

 

		(d)	Change of Control: In the event
that your employment with the Company is terminated by the Company (or its successor) without Cause (as defined in Exhibit A) or
by the Constructive Termination (as defined in Exhibit A) on account of or within twelve (12) months following the date of the consummation
of a Change in Control (as defined Exhibit A), (i) the vesting and exercisability of each of your outstanding stock awards (including
any stock options, restricted stock or other awards granted to you by the Company) shall be automatically accelerated in full, and (ii) you
will be entitled to receive your Salary, Cash Incentive Bonus paid at 100% of target and Benefits, for a period of twelve (12) months.
All payments will be made in accordance with the Company’s normal payroll practices. You agree that as a condition to receiving
any severance compensation, you will execute and deliver to the Company a separation and release agreement pursuant to which you will
release and waive all claims against the Company, its affiliates, and all of its an their present and/or former members, owners, officers,
directors, employees agents attorneys and representatives.

 

		(e)	Compensation Review: In the event the Company completes and initial public offering, the Company
and Board of Directors Compensation Committee agrees to review your full compensation package and make the necessary changes to bring
it in alignment with market standards and the other members of the Akoya executive team.

 

No Other Employment:

You
agree to devote your full business time, attention, and best efforts to the business of Akoya Biosciences, Inc. during the
employment relationship. Akoya Biosciences, Inc.’s normal business hours are from 8:30 a.m. to 5:30 p.m., Monday through
Friday. However, you may be required to work additional hours depending on the nature of your work assignments.

 

Time Off:

Employees at this compensation band are afforded
unlimited PTO under the Akoya PTO policy as stated in the Employee Handbook.

 

Company Holidays:

The Company offers 9 paid Holidays per calendar
year. The company holidays are listed in the benefits guide.

 

Benefit Plans:

You shall be entitled to participate in any standard
health and other benefit plans established by Akoya Biosciences, Inc. on terms as may be established by Akoya Biosciences, Inc.
in its sole discretion. Although you may be eligible for such benefits if they become available in the future, Akoya Biosciences, Inc.
does not promise or represent that such benefits will in fact become available or that once made available they will be continued.

 

Employee Expenses:

Akoya Biosciences, Inc. will reimburse you
for pre-approved business expenses, including those associated with business travel and lodging, (approved by the CEO.), as provided within
the guidelines of Akoya Biosciences, Inc.’s expense policy. All expenses shall be subject to review and approval by your direct
report and the CFO and shall require reasonable documentation.

 

Confidential Information and Invention Assignment
Agreement:

As a condition of your employment with Akoya Biosciences, Inc.,
you acknowledge that you have executed and delivered a copy of Akoya Biosciences, Inc.'s Proprietary Information and Inventions Agreement
and will abide by its terms. You acknowledge that a remedy at law for any breach or threatened breach by you of the provisions of the
Proprietary Information and Inventions Agreement would be inadequate, and you therefore agree that Akoya Biosciences, Inc. shall
be entitled to injunctive relief in case of any such breach or threatened breach.

 

1080
O’Brien Drive. Suite A, Menlo Park, CA 94025 | 855.896.8401 | www.akoyabio.com | 100 Campus Drive, 6th Floor, Marlborough,
MA 01752

 

    

     

    

 

 

 

At-Will Employment:

Employment with Akoya Biosciences, Inc. is
employment at-will. Employment at-will may be terminated with or without cause and with or without notice at any time at the will of either
you or Akoya Biosciences, Inc. Terms and conditions of employment with Akoya Biosciences, Inc. may be modified at the sole discretion
of Akoya Biosciences, Inc. with or without cause and with or without notice. Other than the Chief Executive Officer (“CEO”),
no one has the authority to make any agreement for employment other than for employment at-will or to make any agreement limiting Akoya
Biosciences, Inc.'s discretion to modify the terms and conditions of employment. Only the CEO has the authority to make any such
agreement and then only in writing and signed by each of the CEO and the respective employee. No implied contract concerning any employment-related
decision or term, or condition of employment can be established by any other statement, conduct, policy, or practice.

 

Governing Law:

This Agreement is made and shall be construed
and enforced in accordance with the laws of the State of California. This Agreement and the Exhibits supersede and replace all prior agreements
or understandings, oral or written, between Akoya Biosciences, Inc., and you, except for prior confidentiality agreements, if any.
This Agreement may not be modified except by a writing signed both by the CEO and by you.

 

Arbitration:

In the event of any dispute in connection with
this Agreement or the Exhibits, the parties agree to resolve the dispute by binding arbitration in San Francisco, California, under the
Commercial Arbitration Rules of the American Arbitration Association ("AAA"), with a single arbitrator familiar with employment
and technology agreements appointed by AAA. In the event of any dispute, the prevailing party shall be entitled to its reasonable attorneys'
fees and costs from the other party, whether the matter is litigated or arbitrated to a final judgment or award. The arbitrator's decision
shall be final and binding on all parties and may be entered in any court having competent jurisdiction.

 

Severability:

If any provision of this Agreement or the Exhibits
is determined to be invalid or unenforceable, the remainder shall be unaffected and shall be enforceable against both Akoya Biosciences, Inc.,
and you.

 

This offer is contingent upon a background check
clearance, reference check, drug test, and satisfactory proof of the employee’s right to work in the US, as required by law.

 

Employee Review and Receipt of Agreement:

You acknowledge that you have carefully read and
considered all provisions of this Agreement and the Exhibits and agree that all of the restrictions set forth herein are fair and reasonably
required to protect Akoya Biosciences, Inc.'s interests. You acknowledge that you have received a copy of this Agreement and the
Exhibits as signed by you. You acknowledge that, prior to signing this Agreement, you have had an opportunity to seek the advice of
independent counsel of your choice relating to the terms of this Agreement.

 

	 	Sincerely,
	 	 
	 	Akoya Biosciences, Inc.

 

	 	By:	 
	 	 
	 	Its:	 
	 	 
	 	Date:	 

 

1080
O’Brien Drive. Suite A, Menlo Park, CA 94025 | 855.896.8401 | www.akoyabio.com | 100 Campus Drive, 6th Floor, Marlborough,
MA 01752

 

    

     

    

 

 

 

Agreed to and Accepted:

 

 

 

	 	 	 
	Frederic Pla, Ph.D.	 	[Date]

 

1080
O’Brien Drive. Suite A, Menlo Park, CA 94025 | 855.896.8401 | www.akoyabio.com | 100 Campus Drive, 6th Floor, Marlborough,
MA 01752

 

    

     

    

 

 

 

Exhibit A

 

“Constructive
Termination” shall mean (i) without your written consent, a material reduction in your Annual Salary, Objective-Based
Bonus or Benefits, other than those part of a management-wide reduction, (ii) any material failure by the Company to comply with
the provisions of this Offer, (iii) any action that results in a material diminution in your title, duties or responsibilities unless
such changes are mutually agreed upon, (iv) a failure of a successor-in-interest under a Change of Control to assume all of the obligations
of the company under this Offer, and (v) without your written consent, a requirement of relocation to a location more than 30 miles
away from your current home address. In order to establish a “Constructive Termination” for terminating employment, you must
provide written notice to the Company of the existence of the condition giving rise to the Constructive Termination and the Company must
be provided with thirty (30) days thereafter to cure the condition to the extent that any of such reasons are susceptible to cure, such
satisfaction to be reasonably determined by you.

 

“Cause”
shall mean: (i) any act or omission by you which has an adverse effect on the Company’s
business or on your ability to perform services for the Company, including, without limitation, the commission of, or a guilty or no contest
plea to, any crime (other than ordinary traffic violations), (ii) refusal or failure to perform reasonably assigned duties, serious
misconduct, excessive absenteeism, a breach by you of your fiduciary duty to the Company, or an act of fraud or dishonesty in the performance
of your duties, (iii) refusal or failure to comply with the Company’s policies, or (iv) any breach of your obligations
or duties under any written agreement between the Company and you, including, without limitation, this Offer.

 

“Change
of Control” shall mean the consummation of a reorganization, merger or consolidation, or
sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets of another corporation
or entity, or other similar transaction (each, a “Business Combination”), unless, in each case, immediately following such
Business Combination (A) all or substantially all of the individuals and entities who were the beneficial owners of voting stock
of the Company immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the combined
voting power of the then outstanding shares of voting stock of the entity resulting from such Business Combination (including, without
limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets
either directly or through one or more subsidiaries,) and (B) at least a majority of the members of the Board of Directors of the
entity resulting from such Business Combination were members of the Board of Directors of the Company at the time of the execution of
the initial agreement or of the action of the Board providing for such Business Combination.

 

1080
O’Brien Drive. Suite A, Menlo Park, CA 94025 | 855.896.8401 | www.akoyabio.com | 100 Campus Drive, 6th Floor, Marlborough,
MA 01752

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]